Please try another search
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo, a customized immunotherapeutic vaccine; and COVID-19 prevention vaccines. Cellid, Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Kim Yookyung | - | - | Head of GMP Production Division & Director |
Yuil Kang Chang | - | - | CEO & Representative Director |
Han BeomSoo | - | - | Head of GMP Engineering & Director |
Jeong Saehyeon | - | - | Head of Management Support Team & Executive Director |
Kwak Wiejong | - | 2023 | Non-Executive Director |
Kwon Hyonsoo | - | - | Head of Regulatory Affairs & Director |
Lee Jeonghwa | - | - | Non-Executive Director |
Kim Minsoo | - | - | In charge of Finance/IR(Management Support Office) & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review